Veru (VERU) Stock Price, News & Analysis

Company Overview

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Key Stats

• Today's Range: $0.56 to $0.60
• 50-Day Range: $0.52 to $1.28
• 52-Week Range: $0.47 to $1.92
• Volume: 2.18 million shs
• Average Volume: 6.29 million shs
• Market Capitalization: $86.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Veru Stock Analysis - MarketRank™

Veru scored higher than 50% of companies evaluated by MarketBeat, and ranked 720th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Veru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Veru has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Veru are expected to decrease in the coming year, from ($0.22) to ($0.28) per share.

Price to Book Value per Share Ratio

Veru has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.99% of the outstanding shares of Veru have been sold short.

Short Interest Ratio / Days to Cover

Veru has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Veru has recently increased by 14.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veru does not currently pay a dividend.

Dividend Growth

Veru does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.99% of the outstanding shares of Veru have been sold short.

Short Interest Ratio / Days to Cover

Veru has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Veru has recently increased by 14.31%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.44

News Sentiment

Veru has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Veru this week, compared to 2 articles on an average week.

Search Interest

25 people have searched for VERU on MarketBeat in the last 30 days. This is an increase of 108% compared to the previous 30 days.

MarketBeat Follows

13 people have added Veru to their MarketBeat watchlist in the last 30 days. This is an increase of 86% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Veru insiders have bought more of their company's stock than they have sold. Specifically, they have bought $52,403.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

14.90% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VERU Stock Analysis - Frequently Asked Questions

How have VERU shares performed this year?

Veru's stock was trading at $0.6505 at the start of the year. Since then, VERU stock has decreased by 9.3% and is now trading at $0.5897.
View the best growth stocks for 2025 here.

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) posted its quarterly earnings data on Thursday, February, 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Veru had a negative trailing twelve-month return on equity of 112.75% and a negative net margin of 223.85%.

Who are Veru's major shareholders?

Veru's top institutional investors include MPM Bioimpact LLC (2.93%), Geode Capital Management LLC (2.05%), Adage Capital Partners GP L.L.C. (1.57%) and Oppenheimer & Co. Inc. (0.77%). Insiders that own company stock include Mitchell Shuster Steiner, Harry Fisch, Michael L Rankowitz, K Gary Barnette and Mario Eisenberger.
View institutional ownership trends.

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Veru investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Ford Motor (F), Walt Disney (DIS) and Moderna (MRNA).

Company Calendar

• Last Earnings: 2/13/2025
• Today: 2/21/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Personal Products
• Current Symbol: NASDAQ:VERU
• CUSIP: 31446210
• CIK: 863894
• Web: www.veruhealthcare.com
• Phone: (305) 509-6897
• Fax: 312-595-9122
• Employees: 230
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +578.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-37,800,000.00
• Net Margins: -223.85%
• Pretax Margin: -211.71%
• Return on Equity: -112.75%
• Return on Assets: -67.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.47
• Quick Ratio: 4.47

Sales & Book Value

• Annual Sales: $16.89 million
• Price / Sales: 5.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 3.28

Miscellaneous

• Outstanding Shares: 146,380,000
• Free Float: 124,573,000
• Market Cap: $86.32 million
• Optionable: Optionable
• Beta: -0.54